Cyanocobalamin bufus (Cyanocobalamin bufus)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceCyanocobalaminCyanocobalamin
Similar drugsTo uncover
  • Cyanocobalamin
    solution for injections 
    ATOLL, LLC     Russia
  • Cyanocobalamin
    solution for injections 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Cyanocobalamin
    solution for injections 
    StatusPharm, LLC     Russia
  • Cyanocobalamin
    solution for injections 
    DALHIMFARM, OJSC     Russia
  • Cyanocobalamin
    solution for injections 
    NOVOSIBHIMFARM, OJSC     Russia
  • Cyanocobalamin
    solution for injections 
    BORISOVSKIY FACTORY OF MEDPREPARATES, OJSC     Republic of Belarus
  • Cyanocobalamin
    solution for injections 
    LVIVODIALEK DP KAK UKRMEDPROM     Ukraine
  • Cyanocobalamin (Vitamin B12)
    solution for injections 
    VEROPHARM SA     Russia
  • Cyanocobalamin bufus
    solution
    UPDATE OF PFC, CJSC     Russia
  • Cyanocobalamin bufus
    solution for injections 
    UPDATE OF PFC, CJSC     Russia
  • Cyanocobalamin-Vial
    solution
    VIAL, LLC     Russia
  • Cicomin-Altpharm
    suppositories rect. 
    ALTFARM, LLC     Russia
    • Dosage form: & nbsp
    Injection.

    Composition:
    Active substance:

    Cyanocobalamin - 0.5 mg

    Excipients:

    sodium chloride - 9 mg

    Acetic acid to pH 3.8-5.5

    water for injection up to 1 ml.
    Description:Transparent liquid from bright pink to bright red.
    Pharmacotherapeutic group:Antibiotic-cephalosporin.
    ATX: & nbsp

    B.03.B.A.01   Cyanocobalamin

    Pharmacodynamics:Vitamin B12.In the body (mainly in the liver) is converted to methylcobalamin and 5-deoxyadenosylcobalamin, Methylcobalamin is involved in the reactions of homocysteine ​​conversion into methionine and S-adenosylmethionine-key reactions of the metabolism of pyrimidine and purine bases (and, hence, DNA and RNA). If the vitamin is deficient in this reaction, it may be replaced by menthyltetrahydrofolic acid, while the folicle-like metabolic reactions are disrupted. 5-deoxyadenosylcobalamin serves as a cofactor in the isomerization of L-methylmalonyl-CoA in succinyl-CoA, an important carbohydrate and lipid metabolism reaction. Deficiency of vitamin B12 leads to a violation of the proliferation of rapidly dividing cells of hematopoietic tissue and epithelium, as well as to the violation of the formation of the myelin sheath of neurons.
    Pharmacokinetics:In blood cyanocobalamin binds to the trans-balanamines I and II, which transport it into tissues. It is deposited mainly in the liver. The connection with plasma proteins is 90%. Maximum, the concentration after subcutaneous and intramuscular injection is achieved after 1h.
    From the liver is excreted with bile into the intestine and again absorbed into the blood. Half-life is 500 days.It is excreted at normal kidney function - 7-10% by kidneys, about 50% - by the intestine; with reduced renal function - 0-7% kidney, 70-100% - intestine. Penetrates through the placental barrier, into breast milk.
    Indications:
    Sostonia, accompanied by a deficiency of vitamin B12.
    B12-deficiency anemia; in the complex therapy of anemia (including: iron deficiency, posthemorrhagic, aplastic, anemia, caused by toxic substances and / or drugs).
    In complex therapy:
    In neurology: neuralgia (including trigeminal neuralgia), polyneuropathy (including alcoholic).
    With the preventive purpose - when administering biguanides, paraaminosalicylic acid, ascorbic acid in high doses, abnormalities of the stomach and intestines with impaired absorption of vitamin B12 (partial resection of the stomach, small intestine, Crohn's disease, celiac disease, malabsorption syndrome, sprue), radiation sickness.
    Contraindications:Hypersensitivity, thromboembolism, erythremia, erythrocytosis.
    Carefully:Angina pectoris, benign and malignant neoplasms, accompanied by megaloblastic anemia and vitamin B12 deficiency, propensity to form blood clots.
    Pregnancy and lactation:Use during pregnancy and the period of breastfeeding is allowed according to the indications.
    Dosing and Administration:
    Subcutaneously, intravenously, intramuscularly.
    Subcutaneously, with B12-deficiency anemia - 100-200 mcg / day every other day; with B12-deficiency anemia with addition of a disturbance of the function of the nervous system - 400-500 mcg / day in the first week - daily, then with intervals between administrations up to 5-7 days (simultaneously, prescribe folic acid); during the remission, a maintenance dose of 100 mcg / day 2 times a month, with neurologic symptoms - 200-400 mcg 2-4 times a month.
    In acute posthemorrhagic and iron deficiency anemia - 30-100 mcg 2-3 times a week; at aplastic anemia, anemia caused by toxic substances and / or drugs - 100 μg before the onset of clinical and hematological improvement. With violations from the nervous system - 200-400 mcg 2-4 times a month. In neuralgia: neuralgia (including trigeminal neuralgia), polyneuropathy (including alcoholic) - 200-500 mcg every other day for 2 weeks.
    With a prophylactic goal - 60-100 mcg daily for 20-30 days. To eliminate the deficiency of vitamin B12 is administered intramuscularly or intravenously, 1 mg daily for 1-2 weeks.
    Children of early age with alimentary anemia and premature infants - mildly, 30 mcg daily for 15 days.
    Side effects:Allergic reactions, mental agitation, cardialgia, tachycardia, diarrhea, headache, dizziness, hypercoagulation, violation of purine metabolism.
    Overdose:No data available.
    Interaction:
    Pharmaceutically incompatible with ascorbic acid, heavy metal salts (inactivation, cyanocobalamin), thiamine, pyridoxine, riboflavin (because the cobalt ion contained in the cyanocobalamin molecule destroys other vitamins).
    You can not combine with drugs that increase blood coagulability. The risk of developing allergic reactions increases when combined with thiamine.
    Chloramphenicol reduces the hematopoietic response of cyanocobalamin.
    Do not combine with drugs that increase blood coagulability.
    Special instructions:Deficiency of vitamin B12 should be confirmed diagnostically before prescribing, as it can mask the deficiency of folic acid. During the period of treatment, it is necessary to monitor the parameters of peripheral blood: on the 5th-8th day of treatment, the content of reticulocytes, the concentration of iron is determined.The number of erythrocytes, hemoglobin and color index should be monitored for 1 month 1-2 times a week, and then - 2-4 times a month. The remission is achieved with an increase in the number of red blood cells to 4-4.5 million / μl, when normal erythrocyte sizes reach, aniso- and poikilocytosis disappear, normalizing the number of reticulocytes after a reticulocytic crisis. After reaching hematologic remission, peripheral blood monitoring is performed at least once every 4-6 months. Be careful in individuals prone to thrombosis, with angina (in smaller doses, up to 100 μg per injection).
    Effect on the ability to drive transp. cf. and fur:
    The adverse effect of the drug on the ability to drive vehicles and engage in other activities that require concentration and speed of psychomotor reactions have not been reported. However, given that the drug may cause dizziness, care should be taken when carrying out these activities.
    When used in recommended doses in the elderly; adverse reactions, except for the above listed, was not noted.
    Form release / dosage:
    Solution for injection 0.5 mg / ml.

    Packaging:
    1 ml per ampoule polymer from high-density polyethylene or from low-pressure polyethylene, or from polyethylene for medical purposes, or from polyethylene or polypropylene for infusion solutions and injectables
    On polymer ampoules paste labels from paper label, writing or text labels are applied directly to. ampoule polymer method of drop-jet printing. For 10, 100 ampoules of polymer with instructions for use are placed in a pack of cardboard for consumer containers.
    Storage conditions:In the dark place at a temperature of 15 to 25 ° C. Keep out of the reach of children.
    Shelf life:2 years. Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-000186
    Date of registration:25.01.2011
    Date of cancellation:2016-01-25
    The owner of the registration certificate:UPDATE OF PFC, CJSC UPDATE OF PFC, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp29.11.2015
    Illustrated instructions
      Instructions
      Up